Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-164: Pembrolizumab in MSI-H/dMMR Colorectal Cancer
NCT02460198Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2015
- Primary completion
- Sep 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in colorectal carcinoma (CRC), sponsored by Merck & Co.. Started Aug 2015; status: completed.
02
Drugs
03
Conditions
colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT02460198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02460198.